Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.52 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.52 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.52 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.52 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.43 |
| ▸ | THRA | P10827 | 2/20 | 0.41 |
| ▸ | THRB | P10828 | 2/20 | 0.41 |
| ▸ | GUSB | P08236 | 1/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.40 |
| ▸ | SRC | P12931 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31191892 | 1.00 | GABRA1 (0.52) | GABRA1GABRB1GABRA3GABRB2NR4A2 | |
| SCHEMBL362742 | 0.78 | ALOX5 (0.38) | — | |
| SCHEMBL19839227 | 0.77 | GUSB (0.50) | GABRA1GABRB1GABRA3GABRB2NR4A2 | |
| SCHEMBL8182308 | 0.76 | GABRA1 (0.53) | GABRA1GABRB1GABRA3GABRB2NR4A2 | |
| SCHEMBL20424854 | 0.75 | GABRA1 (0.57) | GABRA1GABRB1GABRA3GABRB2NR4A2 | |
| SCHEMBL27167866 | 0.73 | NPSR1 (0.44) | — | |
| SCHEMBL12253316 | 0.71 | PIN1 (0.43) | THRB | |
| SCHEMBL5739049 | 0.71 | GABRA1 (0.82) | GABRA1GABRB1GABRA3GABRB2NR4A2 | |
| SCHEMBL15093901 | 0.71 | FBP1 (0.39) | — | |
| SCHEMBL21857875 | 0.71 | FBP1 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250197423-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2025-06-19 | — | — | US | disclosed |
| EP-4463231-A1 | RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2024-11-20 | — | — | EP | disclosed |
| WO-2023133543-A1 | RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2023-07-13 | — | — | WO | disclosed |
| WO-2023133543-A1 | RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2023-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250197423-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | GABRA1 3457/4885GABRB1 3621/4885GABRA3 3311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.